Bajaj Healthcare enters into CDMO contract with UK/EU-based companies for 15 new APIs
Thane: Bajaj Healthcare has informed the exchanges that the Company has entered into a definitive contract development and manufacturing organisation (CDMO) contract with UK/EU-based companies for 15 new APIs. This is in addition to 15 molecules for which we entered the contract with UK/EU based clients on 27th February 2024.
The new CDMO pipeline has a mix of, off Patent Generic APIs as well as APIs which are still under patent.
Read also: Bajaj Healthcare enters highly regulated opiate processing business
Speaking at the occasion Anil Jain, Managing Director, Bajaj Healthcare Limited, said, “We are delighted to share this development which reinforces the capabilities that we are building in terms of cost-effective route of synthesis in our R&D and the expansion of manufacturing capabilities, mostly at our USFDA, EU and now TGA, Australia approved site located at Block No. 588, SavliKarachiya Road, At & Post: Gothada, Tal. Savli, Dist: Vadodara, Gujarat."
The company is likely to enter into few CDMO deals with clients in Australia, New Zealand and South Africa, after the approval of the site by the TGA.
Bajaj Healthcare Limited, a manufacturer of APIs, Intermediates and Formulations, was established in the year 1993. It specializes in manufacturing of Intermediates, API, formulations & Nutraceuticals. The company has state-of-art manufacturing facilities, dedicated to APIs, Intermediates and formulation. The Company has a strong presence globally in countries like Europe, USA, Australia, Africa, Middle East and South America.
Read also: USFDA successfully completes inspection at Bajaj Healthcare Vadodara facility
